Full Text Journal Articles by
Author Stuart Pocock

Advertisement

Find full text journal articles






Design of a Prospective Patient-Level Pooled Analysis of Two Parallel Trials of Empagliflozin in Patients With Established Heart Failure.

Milton Packer, Javed Butler, Gerasimos Filippatos, Faiez Zannad, Joao Pedro Ferreira, Cordula Zeller, Martina Brueckmann, Waheed Jamal, Stuart Pocock, Stefan D Anker, ,

The EMPEROR-Reduced trial demonstrated that empagliflozin reduced the combined risk of cardiovascular death or hospitalization for heart failure in patients with a reduced ejection fraction, and the EMPEROR-Preserved trial is currently evaluating the effect of the drug on the same endpoint in patients with an ejection fraction > 40%. However, neither ... Read more >>

Eur J Heart Fail (European journal of heart failure)
[2020, :]

Cited: 0 times

View full text PDF listing >>



Effects of empagliflozin on first and recurrent clinical events in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a secondary analysis of the EMPA-REG OUTCOME trial.

Darren K McGuire, Bernard Zinman, Silvio E Inzucchi, Christoph Wanner, David Fitchett, Stefan D Anker, Stuart Pocock, Stefan Kaspers, Jyothis T George, Maximilian von Eynatten, Odd Erik Johansen, Waheed Jamal, Michaela Mattheus, Ulrich Elsasser, Stefan Hantel, Søren S Lund,

BACKGROUND:Patients with type 2 diabetes and atherosclerotic cardiovascular disease are at high clinical risk. We assessed the effect of the sodium-glucose co-transporter-2 inhibitor, empagliflozin, on total cardiovascular events and admissions to hospital in the EMPA-REG OUTCOME trial. METHODS:The EMPA-REG OUTCOME trial was a randomised, double-blind, non-inferiority trial of patients (aged ... Read more >>

Lancet Diabetes Endocrinol (The lancet. Diabetes & endocrinology)
[2020, 8(12):949-959]

Cited: 0 times

View full text PDF listing >>



Advertisement

Baseline Characteristics of Patients with Heart Failure with Preserved Ejection Fraction in the EMPEROR-Preserved Trial.

Stefan D Anker, Javed Butler, Gerasimos Filippatos, Muhammad Shahzeb Khan, João Pedro Ferreira, Edimar Bocchi, Michael Böhm, Hans Pieter Brunner-La Rocca, Dong-Ju Choi, Vijay Chopra, Eduardo Chuquiure, Nadia Giannetti, Juan Esteban Gomez-Mesa, Stefan Janssens, James L Januzzi, Jose R Gonzalez-Juanatey, Bela Merkely, Stephen J Nicholls, Sergio V Perrone, Ileana L Piña, Piotr Ponikowski, Michele Senni, Marie-France Seronde, David Sim, Jindrich Spinar, Iain Squire, Stefano Taddei, Hiroyuki Tsutsui, Subodh Verma, Dragos Vinereanu, Jian Zhang, Waheed Jamal, Sven Schnaidt, Janet M Schnee, Martina Brueckmann, Stuart J Pocock, Faiez Zannad, Milton Packer, ,

<b>Background: </b>EMPEROR-Preserved is an ongoing trial evaluating the effect of empagliflozin in patients with heart failure with preserved ejection fraction (HFpEF). This report describes the baseline characteristics of the EMPEROR-Preserved cohort and compares it with patients enrolled in prior HFpEF trials.<br><br><b>Methods: </b>EMPEROR-Preserved is a phase III randomized, international, double-blind, parallel-group, ... Read more >>

Eur J Heart Fail (European journal of heart failure)
[2020, :]

Cited: 0 times

View full text PDF listing >>



Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial.

Piotr Ponikowski, Bridget-Anne Kirwan, Stefan D Anker, Theresa McDonagh, Maria Dorobantu, Jarosław Drozdz, Vincent Fabien, Gerasimos Filippatos, Udo Michael Göhring, Andre Keren, Irakli Khintibidze, Hans Kragten, Felipe A Martinez, Marco Metra, Davor Milicic, José C Nicolau, Marcus Ohlsson, Alexander Parkhomenko, Domingo A Pascual-Figal, Frank Ruschitzka, David Sim, Hadi Skouri, Peter van der Meer, Basil S Lewis, Josep Comin-Colet, Stephan von Haehling, Alain Cohen-Solal, Nicolas Danchin, Wolfram Doehner, Henry J Dargie, Michael Motro, Javed Butler, Tim Friede, Klaus H Jensen, Stuart Pocock, Ewa A Jankowska, ,

BACKGROUND:Intravenous ferric carboxymaltose has been shown to improve symptoms and quality of life in patients with chronic heart failure and iron deficiency. We aimed to evaluate the effect of ferric carboxymaltose, compared with placebo, on outcomes in patients who were stabilised after an episode of acute heart failure. METHODS:AFFIRM-AHF was ... Read more >>

Lancet (Lancet (London, England))
[2020, :]

Cited: 0 times

View full text PDF listing >>



Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status - Results from the EMPEROR-Reduced Trial.

Stefan D Anker, Javed Butler, Gerasimos Filippatos, Muhammad Shahzeb Khan, Nikolaus Marx, Carolyn S P Lam, Sven Schnaidt, Anne Pernille Ofstad, Martina Brueckmann, Waheed Jamal, Edimar Bocchi, Piotr Ponikowski, Sergio V Perrone, James L Januzzi, Subodh Verma, Michael Böhm, João Pedro Ferreira, Stuart J Pocock, Faiez Zannad, Milton Packer, ,

Background: Sodium-glucose cotransporter 2 (SGLT2) inhibitors improve outcomes in patients with heart failure with reduced ejection fraction, but additional information is needed about whether glycemic status influences the magnitude of their benefits on heart failure and renal events. Methods: Patients with class II-IV heart failure and a left ventricular ejection ... Read more >>

Circulation (Circulation)
[2020, :]

Cited: 0 times

View full text PDF listing >>



Prioritized Endpoints for Device-Based Hypertension Trials: the Win Ratio Methodology.

David E Kandzari, Graeme L Hickey, Stuart J Pocock, Michael A Weber, Michael Böhm, Sidney A Cohen, Martin Fahy, Giuseppina Lamberti, Felix Mahfoud,

AIMS:Multiple endpoints with varying clinical relevance are available to establish the efficacy of device-based treatments. We propose a novel prioritized endpoint framework for determining the treatment benefit of renal denervation (RDN) compared with sham control. METHODS AND RESULTS:We analysed the SPYRAL HTN-ON MED pilot study data using a prioritized hierarchical ... Read more >>

EuroIntervention (EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology)
[2020, :]

Cited: 0 times

View full text PDF listing >>



Long-term antiplatelet therapy in medically managed non-ST-segment elevation acute coronary syndromes: The EPICOR Asia study.

Juan Zhou, Chee Tang Chin, Xin Huang, Ning Guo, Yue Wu, Bo Yu, Shubin Qiao, Jiyan Chen, Yaling Han, Junbo Ge, Stuart J Pocock, Yong Huo, Zhaohong Wang, Zuyi Yuan,

OBJECTIVES:To describe long-term antithrombotic management patterns (AMPs) in medically managed Asian patients with non-ST-segment myocardial infarction (NSTEMI) or unstable angina (UA). BACKGROUND:Current guidelines support an early invasive strategy in NSTEMI and UA patients, but many are medically managed, and data are limited on long-term AMPs in Asia. METHODS:Data were analyzed ... Read more >>

Int J Cardiol (International journal of cardiology)
[2020, :]

Cited: 0 times

View full text PDF listing >>



Diabetes association with self-reported health, resource utilization, and prognosis post-myocardial infarction.

José C Nicolau, David Brieger, Ruth Owen, Remo H M Furtado, Shaun G Goodman, Mauricio G Cohen, Tabassome Simon, Dirk Westermann, Christopher B Granger, Richard Grieve, Satoshi Yasuda, Jiyan Chen, Katarina Hedman, Carl Mellström, Gunnar Brandrup-Wognsen, Stuart J Pocock,

BACKGROUND:Diabetes mellitus (DM) is associated with increased cardiovascular (CV) risk. We compared health-related quality of life (HRQoL), healthcare resource utilization (HRU), and clinical outcomes of stable post-myocardial infarction (MI) patients with and without DM. HYPOTHESIS:In post-MI patients, DM is associated with worse HRQoL, increased HRU, and worse clinical outcomes. METHODS:The ... Read more >>

Clin Cardiol (Clinical cardiology)
[2020, :]

Cited: 0 times

View full text PDF listing >>



Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights from the EMPEROR-Reduced Trial.

Faiez Zannad, João Pedro Ferreira, Stuart J Pocock, Cordula Zeller, Stefan D Anker, Javed Butler, Gerasimos Filippatos, Sibylle Jenny Hauske, Martina Brueckmann, Egon Pfarr, Janet Schnee, Christoph Wanner, Milton Packer,

Background: In EMPEROR-Reduced, empagliflozin reduced cardiovascular death or HF hospitalization, total HF hospitalizations, and slowed the progressive decline in kidney function in patients with HF and a reduced ejection fraction (HFrEF), with and without diabetes. We aim to study the effect of empagliflozin on cardiovascular and kidney outcomes across the ... Read more >>

Circulation (Circulation)
[2020, :]

Cited: 0 times

View full text PDF listing >>



Effect of Empagliflozin on the Clinical Stability of Patients with Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial.

Milton Packer, Stefan D Anker, Javed Butler, Gerasimos S Filippatos, João Pedro Ferreira, Stuart Pocock, Peter E Carson, Inder S Anand, Wolfram Doehner, Markus Haass, Michel Komajda, Alan B Miller, Steen Pehrson, John R Teerlink, Martina Brueckmann, Waheed Jamal, Cordula Zeller, Sven Schnaidt, Faiez Zannad, ,

Background: Empagliflozin reduces the risk of cardiovascular death or hospitalization for heart failure in patients with heart failure and a reduced ejection fraction, with or without diabetes, but additional data are needed about the effect of the drug on inpatient and outpatient events that reflect worsening heart failure. Methods: We ... Read more >>

Circulation (Circulation)
[2020, :]

Cited: 0 times

View full text PDF listing >>



Relationship between nitrate headache and outcome in patients with acute stroke: results from the efficacy of nitric oxide in stroke (ENOS) trial.

Lucy Beishon, Lisa J Woodhouse, Daniel Bereczki, Hanne K Christensen, Ronan Collins, John Gommans, Christina Kruuse, George Ntaios, Serefnur Ozturk, Stephen Phillips, Stuart Pocock, Szabolcs Szatmari, Joanna Wardlaw, Nikola Sprigg, Philip M Bath, ,

INTRODUCTION:Nitrate-induced headache is common and may signify responsive cerebral vasculature. We assessed the relationship between nitrate headache and outcome in patients with acute stroke. MATERIALS AND METHODS:Patients were those randomised to glyceryl trinitrate (GTN) versus no GTN in the efficacy of nitric oxide in stroke trial. Development of headache by ... Read more >>

Stroke Vasc Neurol (Stroke and vascular neurology)
[2020, :]

Cited: 0 times

View full text PDF listing >>



The age of randomized clinical trials: three important aspects of randomized clinical trials in cardiovascular pharmacotherapy with examples from lipid, diabetes, and antithrombotic trials.

Heinz Drexel, Basil S Lewis, Giuseppe M C Rosano, Christoph H Saely, Gerda Tautermann, Kurt Huber, Joern F Dopheide, Juan Carlos Kaski, Arthur Mader, Alexander Niessner, Gianluigi Savarese, Thomas A Schmidt, AnneGrete Semb, Juan Tamargo, Sven Wassmann, Keld Per Kjeldsen, Stefan Agewall, Stuart J Pocock,

Eur Heart J Cardiovasc Pharmacother (European heart journal. Cardiovascular pharmacotherapy)
[2020, :]

Cited: 0 times

View full text PDF listing >>



Rationale and design of ApoA-I Event Reducing in Ischemic Syndromes II (AEGIS-II): A phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to investigate the efficacy and safety of CSL112 in subjects after acute myocardial infarction.

C Michael Gibson, John J P Kastelein, Adam T Phillips, Philip E Aylward, Megan K Yee, Michal Tendera, Stephen J Nicholls, Stuart Pocock, Shaun G Goodman, John H Alexander, A Michael Lincoff, Christoph Bode, Danielle Duffy, Mark Heise, Gail Berman, Sojaita Jenny Mears, Pierluigi Tricoci, Lawrence I Deckelbaum, P Gabriel Steg, Paul Ridker, Roxana Mehran,

Acute myocardial infarction (MI) patients remain at high risk for recurrent events. Cholesterol efflux, mediated by apolipoprotein A-I, removes excess cholesterol from atherosclerotic plaque and transports it to the liver for excretion. Impaired cholesterol efflux is associated with higher cardiovascular (CV) event rates among both patients with stable coronary artery ... Read more >>

Am Heart J (American heart journal)
[2020, :]

Cited: 0 times

View full text PDF listing >>



Estimating the Lifetime Benefits of Treatments for Heart Failure.

João Pedro Ferreira, Kieran F Docherty, Susan Stienen, Pardeep S Jhund, Brian L Claggett, Scott D Solomon, Mark C Petrie, John Gregson, Stuart J Pocock, Faiez Zannad, John J V McMurray,

OBJECTIVES:This study compared ways of describing treatment effects. The objective was to better explain to clinicians and patients what they might expect from a given treatment, not only in terms of relative and absolute risk reduction, but also in projections of long-term survival. BACKGROUND:The restricted mean survival time (RMST) can ... Read more >>

JACC Heart Fail (JACC. Heart failure)
[2020, :]

Cited: 0 times

View full text PDF listing >>



Ticagrelor alone vs. ticagrelor plus aspirin following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes: TWILIGHT-ACS.

Usman Baber, George Dangas, Dominick Joseph Angiolillo, David Joel Cohen, Samin Kumar Sharma, Johny Nicolas, Carlo Briguori, Jin Yu Cha, Timothy Collier, Dariusz Dudek, Vladimir Džavik, Javier Escaned, Robert Gil, Paul Gurbel, Christian W Hamm, Timothy Henry, Kurt Huber, Adnan Kastrati, Upendra Kaul, Ran Kornowski, Mitchell Krucoff, Vijay Kunadian, Steven Owen Marx, Shamir Mehta, David Moliterno, Erik Magnus Ohman, Keith Oldroyd, Gennaro Sardella, Samantha Sartori, Richard Shlofmitz, Philippe Gabriel Steg, Giora Weisz, Bernhard Witzenbichler, Ya-Ling Han, Stuart Pocock, Charles Michael Gibson, Roxana Mehran,

AIMS :The aim of this study was to determine the effect of ticagrelor monotherapy on clinically relevant bleeding and major ischaemic events in relation to clinical presentation with and without non-ST elevation acute coronary syndromes (NSTE-ACS) among patients undergoing percutaneous coronary intervention (PCI) with drug-eluting stents (DES). METHODS AND RESULTS :We conducted ... Read more >>

Eur Heart J (European heart journal)
[2020, 41(37):3533-3545]

Cited: 0 times

View full text PDF listing >>



Validation of high bleeding risk criteria and definition as proposed by the academic research consortium for high bleeding risk.

Noé Corpataux, Alessandro Spirito, Felice Gragnano, Lukas Vaisnora, Roberto Galea, Stefano Svab, Giuseppe Gargiulo, Thomas Zanchin, Christian Zanchin, George C M Siontis, Fabien Praz, Jonas Lanz, Lukas Hunziker, Stefan Stortecky, Thomas Pilgrim, Lorenz Räber, Davide Capodanno, Philip Urban, Stuart Pocock, Dik Heg, Stephan Windecker, Marco Valgimigli,

AIMS:To validate the set of clinical and biochemical criteria proposed by consensus by the Academic Research Consortium (ARC) for High Bleeding Risk (HBR) for the identification of HBR patients. These criteria were categorized into major and minor, if expected to carry in isolation, respectively, ≥4% and <4% Bleeding Academic Research ... Read more >>

Eur Heart J (European heart journal)
[2020, 41(38):3743-3749]

Cited: 0 times

View full text PDF listing >>



Implications of Alternative Definitions of Peri-Procedural Myocardial Infarction After Coronary Revascularization.

John Gregson, Gregg W Stone, Ori Ben-Yehuda, Björn Redfors, David E Kandzari, Marie-Claude Morice, Martin B Leon, Ioanna Kosmidou, Nicholas J Lembo, W Morris Brown, Dimitri Karmpaliotis, Adrian P Banning, Jose Pomar, Manel Sabaté, Charles A Simonton, Ovidiu Dressler, Arie Pieter Kappetein, Joseph F Sabik, Patrick W Serruys, Stuart J Pocock,

BACKGROUND:Varying definitions of procedural myocardial infarction (PMI) are in widespread use. OBJECTIVES:This study sought to determine the rates and clinical relevance of PMI using different definitions in patients with left main coronary artery disease randomized to percutaneous coronary intervention (PCI) versus coronary artery bypass grafting (CABG) surgery in the EXCEL ... Read more >>

J Am Coll Cardiol (Journal of the American College of Cardiology)
[2020, 76(14):1609-1621]

Cited: 0 times

View full text PDF listing >>



The win ratio approach for composite endpoints: practical guidance based on previous experience.

Björn Redfors, John Gregson, Aaron Crowley, Thomas McAndrew, Ori Ben-Yehuda, Gregg W Stone, Stuart J Pocock,

The win ratio was introduced in 2012 as a new method for examining composite endpoints and has since been widely adopted in cardiovascular (CV) trials. Improving upon conventional methods for analysing composite endpoints, the win ratio accounts for relative priorities of the components and allows the components to be different ... Read more >>

Eur Heart J (European heart journal)
[2020, :]

Cited: 0 times

View full text PDF listing >>



Metformin discontinuation in patients beginning second-line glucose-lowering therapy: results from the global observational DISCOVER study programme.

Kamlesh Khunti, Marilia B Gomes, Mikhail Kosiborod, Antonio Nicolucci, Stuart Pocock, Wolfgang Rathmann, Marina V Shestakova, Iichiro Shimomura, Hirotaka Watada, Hungta Chen, Javier Cid-Ruzafa, Peter Fenici, Niklas Hammar, Fengming Tang, Linong Ji, ,

OBJECTIVES:To evaluate the extent to which patients with type 2 diabetes discontinue metformin therapy when initiating second-line treatment and factors associated with metformin discontinuation, using baseline data from the DISCOVER study programme. DESIGN:DISCOVER is a 3-year, prospective, observational study programme including data from 38 countries across 6 continents from 2014 ... Read more >>

BMJ Open (BMJ open)
[2020, 10(8):e034613]

Cited: 0 times

View full text PDF listing >>



Trial Design Principles for Patients at High Bleeding Risk Undergoing PCI: JACC Scientific Expert Panel.

Davide Capodanno, Marie-Claude Morice, Dominick J Angiolillo, Deepak L Bhatt, Robert A Byrne, Roisin Colleran, Thomas Cuisset, Donald Cutlip, Pedro Eerdmans, John Eikelboom, Andrew Farb, C Michael Gibson, John Gregson, Michael Haude, Stefan K James, Hyo-Soo Kim, Takeshi Kimura, Akihide Konishi, Martin B Leon, P F Adrian Magee, Yoshiaki Mitsutake, Darren Mylotte, Stuart J Pocock, Sunil V Rao, Ernest Spitzer, Norman Stockbridge, Marco Valgimigli, Olivier Varenne, Ute Windhovel, Mitchel W Krucoff, Philip Urban, Roxana Mehran,

Investigating the balance of risk for thrombotic and bleeding events after percutaneous coronary intervention (PCI) is especially relevant for patients at high bleeding risk (HBR). The Academic Research Consortium for HBR recently proposed a consensus definition in an effort to standardize the patient population included in HBR trials. The aim ... Read more >>

J Am Coll Cardiol (Journal of the American College of Cardiology)
[2020, 76(12):1468-1483]

Cited: 0 times

View full text PDF listing >>



SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials.

Faiez Zannad, João Pedro Ferreira, Stuart J Pocock, Stefan D Anker, Javed Butler, Gerasimos Filippatos, Martina Brueckmann, Anne Pernille Ofstad, Egon Pfarr, Waheed Jamal, Milton Packer,

BACKGROUND:Both DAPA-HF (assessing dapagliflozin) and EMPEROR-Reduced (assessing empagliflozin) trials showed that sodium-glucose co-transporter-2 (SGLT2) inhibition reduced the combined risk of cardiovascular death or hospitalisation for heart failure in patients with heart failure with reduced ejection fraction (HFrEF) with or without diabetes. However, neither trial was powered to assess effects on ... Read more >>

Lancet (Lancet (London, England))
[2020, 396(10254):819-829]

Cited: 1 time

View full text PDF listing >>



Global patterns of comprehensive cardiovascular risk factor control in patients with type 2 diabetes mellitus: Insights from the DISCOVER study.

Krishna K Patel, Marilia B Gomes, Bernard Charbonnel, Hungta Chen, Javier Cid-Ruzafa, Peter Fenici, Niklas Hammar, Linong Ji, Kevin F Kennedy, Kamlesh Khunti, Mikhail Kosiborod, Stuart Pocock, Marina V Shestakova, Iichiro Shimomura, Filip Surmont, Hirotaka Watada, Suzanne V Arnold,

AIM:To investigate global patterns of cardiovascular risk factor control in patients with type 2 diabetes mellitus (T2D). METHODS:DISCOVER is an international, observational cohort study of patients with T2D beginning second-line glucose-lowering therapy. Risk factor management was examined among eligible patients (ie, those with the risk factor) at study baseline. Inter-country ... Read more >>

Diabetes Obes Metab (Diabetes, obesity & metabolism)
[2020, :]

Cited: 0 times

View full text PDF listing >>



Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure.

Milton Packer, Stefan D Anker, Javed Butler, Gerasimos Filippatos, Stuart J Pocock, Peter Carson, James Januzzi, Subodh Verma, Hiroyuki Tsutsui, Martina Brueckmann, Waheed Jamal, Karen Kimura, Janet Schnee, Cordula Zeller, Daniel Cotton, Edimar Bocchi, Michael Böhm, Dong-Ju Choi, Vijay Chopra, Eduardo Chuquiure, Nadia Giannetti, Stefan Janssens, Jian Zhang, Jose R Gonzalez Juanatey, Sanjay Kaul, Hans-Peter Brunner-La Rocca, Bela Merkely, Stephen J Nicholls, Sergio Perrone, Ileana Pina, Piotr Ponikowski, Naveed Sattar, Michele Senni, Marie-France Seronde, Jindrich Spinar, Iain Squire, Stefano Taddei, Christoph Wanner, Faiez Zannad, ,

BACKGROUND:Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of hospitalization for heart failure in patients regardless of the presence or absence of diabetes. More evidence is needed regarding the effects of these drugs in patients across the broad spectrum of heart failure, including those with a markedly reduced ejection fraction. ... Read more >>

N Engl J Med (The New England journal of medicine)
[2020, 383(15):1413-1424]

Cited: 4 times

View full text PDF listing >>



Drug-Coated Stents Versus Bare-Metal Stents in Academic Research Consortium-Defined High Bleeding Risk Patients.

Guillaume Marquis-Gravel, Philip Urban, Samuel Copt, Davide Capodanno, Stuart J Pocock, Sara Sadozai Slama, Hans-Peter Stoll, Jean-François Tanguay, Roxana Mehran, Martin B Leon, Sunil V Rao, Marie-Claude Morice, Mitchell W Krucoff,

AIMS:To model the safety and effectiveness of drug-coated stents (DCS) vs. bare-metal stents (BMS) in high bleeding risk (HBR) patients according to the Academic Research Criteria (ARC) criteria. METHODS AND RESULTS:Participants from the LEADERS FREE (LF) and LEADERS FREE (LFII) studies were pooled into one dataset. Participants were treated with ... Read more >>

EuroIntervention (EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology)
[2020, :]

Cited: 0 times

View full text PDF listing >>



Long-term antithrombotic management patterns in Asian patients with acute coronary syndrome: 2-year observations from the EPICOR Asia study.

Bo Zheng, Yong Huo, Stephen W-L Lee, Jitendra P S Sawhney, Hyo-Soo Kim, Rungroj Krittayaphong, Stuart J Pocock, Vo T Nhan, Angeles Alonso Garcia, Chee Tang Chin, Jie Jiang, Stephen Jan, Ana Maria Vega, Nobuya Hayashi, Tiong K Ong,

BACKGROUND:Despite guideline recommendations, dual antiplatelet therapy (DAPT) is frequently used for longer than 1 year after an acute coronary syndrome (ACS) event. In Asia, information on antithrombotic management patterns (AMPs), including DAPT post discharge, is sparse. This analysis evaluated real-world AMPs up to 2 years post discharge for ACS. HYPOTHESIS:There is ... Read more >>

Clin Cardiol (Clinical cardiology)
[2020, 43(9):999-1008]

Cited: 1 time

View full text PDF listing >>



Advertisement

Disclaimer
1.368 s